Peptide and a use thereof

ABSTRACT

The disclosure relates to a peptide (SEQ ID NO: 5), the use of said peptide for the treatment of the symptoms associated with pain, the use of said peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide.

FIELD OF THE INVENTION

This disclosure relates to protein identification and pharmaceuticalsfields. In particular, it relates to a natural peptide having potentanalgesic effects and anti-influenza virus effect, its encodingpolynucleotide, the preparation and uses thereof and a pharmaceuticalcomposition containing said peptide.

BACKGROUND OF THE INVENTION

Pain is an unpleasant feeling often caused by intense or damagingstimuli. The International Association for the Study of Pain's widelydefined ‘pain’ as “an unpleasant sensory and emotional experienceassociated with actual or potential tissue damage, or described in termsof such damage” (Pain 1979; 6:247-8). Pain is the most common reason forphysician consultation in the United States (Raj P P. Taxonomy andclassification of pain. In: Niv D, Kreitler S, Diego B, Lamberto A. TheHandbook of Chronic Pain. Nova Biomedical Books 2007). It is a majorsymptom in many medical conditions, and can significantly interfere witha person's quality of life and general functioning (Breivik H,Borchgrevink P C, Allen S M, Rosseland L A, Romundstad L, Hals E K,Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008;101(1):17-24). In most cases, pain is usually transitory, lasting onlyuntil the noxious stimulus is removed or the underlying damage orpathology has healed. However, some painful conditions, such asrheumatoid arthritis, peripheral neuropathy, cancer and idiopathic pain,may persist for years. Pain that lasts a long time is called ‘chronic’,and pain that resolves quickly is called ‘acute’. Traditionally, thedistinction between acute and chronic pain has relied upon an arbitraryinterval of time from onset; the two most commonly used markers are 3months and 6 months since the onset of pain (Turk D C, Okifuji A. Painterms and taxonomies of pain. In: Bonica J J, Loeser J D, Chapman C R,Turk D C, Butler S H. Bonica's management of pain. Hagerstwon, Md.:Lippincott Williams & Wilkins; 2001), though some researchers haveplaced the transition from acute to chronic pain at 12 months (SpanswickC C, Main C J. Pain management: an interdisciplinary approach.Edinburgh: Churchill Livingstone 2000). Others apply ‘acute’ to painthat lasts less than 30 days, ‘chronic’ to pain of more than six months,and ‘subacute’ to pain that lasts from one to six months (Thienhaus O,Cole B E. Classification of pain. In: Weiner R. Pain management: apractical guide for clinicians. Boca Raton: CRC Press; 2002).

In humans, the detection of peripheral pain begins at free nerveendings. The polymodal pain receptors and high thresholdmechanoreceptors detect noxious stimuli such as strong mechanicalforces, H⁺, K⁺, chemicals, and temperature. After detection of thestimuli, the sensation of pain travels from the periphery to the spinalcord (i.e., the spinothalamic tract), then decussate and cross via theanterior white commissure (in the spinal cord) before ascendingcontralaterally. Before reaching the brain, the spinothalamic tractsplits into the lateral neo-spinothalamic tract and the medialpaleo-spinothalamic tract (Skevington, S. M. Psychology of pain.Chichester, UK: Wile 1995; p 18), subsequently terminating at theventral posterolateral nucleus of the thalamus, where they synapse ondendrites of the somatosensory cortex. Apart from noxious stimulicausing pain, injuries to a peripheral nerve in humans often results ina persistent neuropathic pain condition that is characterized byspontaneous, usually burning pain, allodynia (pain responses tonon-noxious stimuli) and hyperalgesia (exaggerated pain responses tonoxious stimuli). Although sympatholytic therapy is sometimes effectivefor relief of the pain, indicating that neuropathic pain is at leastpartly maintained by activity in the sympathetic nervous system, manypatients do not respond. The effectiveness of opioids for neuropathicpain is also limited (Rowbotham M C. Ann Neurol 1994; 35:S46-S49), andsomewhat controversial.

Acute pain is usually managed with medications such as analgesics andanesthetics. Management of chronic pain or neuropathic pain, however, ismuch more difficult. Many drugs help relieving acute pain, and ingeneral they can be divided into non-opiod and opiod drugs. Thenon-opiod drugs include non-steroid anti-inflammatory drugs (NSAIDs),such as acetylsalicylic acid (aspirin) and COX-2 (cyclooxygenase-2)inhibitors. The term “nonsteroidal” in NSAIDs is used to distinguishthese drugs from steroids, which, among a broad range of other effects,have a similar eicosanoid-depressing, anti-inflammatory action. Asanalgesics, NSAIDs are unusual in that they are non-narcotic. NSAIDs areusually indicated for the treatment of acute or chronic conditions wherepain and inflammation are present.

Aspirin is often used as an analgesic to relieve minor aches and pains,as an antipyretic to reduce fever, or as an anti-inflammatorymedication. Aspirin works well for dull, throbbing pain, but it isineffective for pain caused by most muscle cramps, bloating, visceraldistension, and acute skin irritation. As a post-surgery painkiller,aspirin is inferior to one of the NSAIDs ibuprofen and has a highergastrointestinal toxicity. Furthermore, aspirin also has manycontraindications and undesirable effects; for example, the use ofaspirin needs to be cautious in people with peptic ulcers, milddiabetes, or gastritis. Even if none of these conditions is present,there is still an increased risk of stomach bleeding. The other categoryof NSAIDs is COX-2 selective inhibitor that directly targets COX-2, anenzyme responsible for inflammation and pain. Targeting selectivity forCOX-2 reduces the risk of peptic ulceration, and is the main feature ofcelecoxib, rofecoxib and other members of this drug category. COX-2inhibitors also have adverse effects, most notably an increased risk ofrenal failure, and some results have shown an increase in the risk forheart attack, thrombosis and stroke by a relative increase inthromboxane. Of note, Rofecoxib (commonly known as Vioxx) was taken offthe market in 2004 because of these concerns.

An alternative category of analgesics is opioid drugs. An opioid is apsychoactive chemical that works by binding to opioid receptors, whichare found principally in the central and peripheral nervous system andthe gastrointestinal tract. The receptors in these organ systems mediateboth the beneficial effects and the side effects of opioids. Theanalgesic effects of opioids are due to decreased perception of pain,decreased reaction to pain as well as increased pain tolerance. Opioidshave long been used to treat acute pain (such as post-operative pain),and are invaluable in palliative care to alleviate the severe, chronic,disabling pain of terminal conditions such as cancer, and degenerativeconditions such as rheumatoid arthritis. However, opioids should be usedvery cautiously in chronic non-cancer pain. High doses are notnecessarily required to control the pain of advanced or end-stagedisease. Tolerance (a physical reaction making the body less responsiveto analgesic and other effects) is very likely to occur, making theopioid as the last option for pain control.

From the discussion above, it is clear that there is an urgent need todevelop a new class of effective non-tolerant and non-sedativeanalgesics for controlling both severe acute pain and chronic pain.

A mixture of bioactive agents extracted from skin tissue of rabbits withinflammation elicited by inoculation of the virus Vaccinia variolae,which contain inhibitors against the kallikrein-kinin system, has beenused for treatment of pain for decades (K. Ono, A. Inoue, and M.Nakamuro. Jpn Pharmacol Ther, 1981; 9:299-307). Pharmacological andclinical experiments showed that such a mixture of bioactive agentsprepared from the rabbit skin have analgesic effects against all kindsof symptomatic neuralgia, lumbago, cholecystagia, angina, arterialembolism pains, acute pains from wound, burn and scald, pains in surgeryor post-surgery, peptic ulcer pain, dysmenorrhea, labor pains posteriorto childbirth, headache, pains induced by various tumor and so on.Studies also showed that the this mixture of bioactive agents caneffectively promote activation of macrophage, significantly inhibit theactivity of anti-complement in type II allergic reaction. The effectshave linear correlation with the doses. So the drugs have effects oninhibiting inflammatory reaction correlated with immunity and improvingimmunity function. Furthermore, after a continuous 28-dayintraperitoneally administration of the drugs prepared from the rabbitskin in rats, no rats died and no changes induced by the drugs existedin examinations of urine, eye, blood biochemistry, pathology andanatomy. Therefore, such analgesic drugs have little toxic effects (SeeUS Patent application number: 20110003009). However, although peptideresearch on drug design and drug discovery is one of the most promisingfields in the development of the new drug, there was no report that theresearchers in this field focus on searching the active proteiningredients in the mixture, even though such a mixture has been in themarket for several decades and with good effects for analgesia.Therefore, identification of the active ingredient(s) will helpunderstanding the acting mechanism(s), and purification of the exactcomponents responsible for analgesic effects will facilitate thepreparation of well-delineated drug(s) for clinical use.

Influenzavirus A is a genus of the Orthomyxoviridae family of viruses.Strains of all subtypes of influenza A virus have been isolated fromwild birds, although disease is uncommon. Some isolates of influenza Avirus cause severe disease both in domestic poultry and, rarely, inhumans (“Avian influenza (” bird flu“)—Fact sheet”. WHO.) Occasionally,viruses are transmitted from wild aquatic birds to domestic poultry, andthis may cause an outbreak or give rise to human influenza pandemics(Klenk, et al. (2008). “Avian Influenza: Molecular Mechanisms ofPathogenesis and Host Range”. Animal Viruses: Molecular Biology. CaisterAcademic Press & Kawaoka Y, ed. (2006). Influenza Virology: CurrentTopics. Caister Academic Press). Influenza A viruses are negative sense,single-stranded, segmented RNA viruses. There are several subtypes,labeled according to an H number (for the type of hemagglutinin) and anN number (for the type of neuraminidase). There are at least 16different H antigens (H1 to H16) and nine different N antigens (N1 toN9). Different influenza viruses encode for different hemagglutinin andneuraminidase proteins; for example, the H5N1 virus designates aninfluenza A subtype that has a type 5 hemagglutinin (H) protein and atype 1 neuraminidase (N) protein. Furthermore, each virus subtype hasmutated into a variety of strains with differing pathogenic profiles;some are pathogenic to one species but not others, and some arepathogenic to multiple species. Theoretically, 144 differentcombinations of these proteins are possible (“Influenza Viruses”.Centers for Disease Control and Prevention. Nov. 18, 2005). Somevariants are identified and named according to the isolate theyresemble, thus are presumed to share lineage (example: Fujian fluvirus-like), according to their typical host (example: human flu virus),according to their subtype (example: H3N2), and according to theirdeadliness (example: LP, low pathogenic). So a flu from a virus similarto the isolate A/Fujian/411/2002(H3N2) is called Fujian flu, human flu,or H3N2 flu. “Human influenza virus” usually refers to those subtypesthat spread widely among humans. Amongst all strains, H1N1, H1N2, andH3N2 are the only known influenza A virus subtypes currently circulatingamong humans (CDC, USA: Key Facts About Avian Influenza (Bird Flu) andAvian Influenza A (H5N1) Virus). Treatments for influenza include arange of medications and therapies that are used in response to diseaseinfluenza. Treatments may either directly target the influenza virusitself; or instead they may just offer relief to symptoms of thedisease, while the body's own immune system works to recover frominfection (Montalto N J, Gum K D, Ashley J V (2000). “Updated treatmentfor influenza A and B”. Am Fam Physician 62 (11): 2467-76). The two mainclasses of antiviral drugs used against influenza viruses areneuraminidase inhibitors, such as zanamivir and oseltamivir, orinhibitors of the viral M2 protein, such as amantadine and rimantadine.These drugs can reduce the severity of symptoms if taken soon afterinfection and can also be taken to decrease the risk of infection.However, viral strains have emerged with drug resistance to both classesof drug. Like the development of bacterial antibiotic resistance, thiscan result from over-use of these drugs. For example, a recent studyemphasized the urgent need for augmentation of oseltamivir (Tamiflu)stockpiles with additional antiviral drugs including zanamivir (Relenza)based on an evaluation of the performance of these drugs in the scenariothat the 2009 H1N1 ‘Swine Flu’ neuraminidase (NA) were to acquire thetamiflu-resistance (His274Tyr) mutation which is currently widespread inseasonal H1N1 strains (Venkataramanan Soundararajan, KannanTharakaraman, Rahul Raman, S. Raguram, Zachary Shriver, V. Sasisekharan,Ram Sasisekharan (2009). “Extrapolating from sequence—the 2009 H1N1‘swine’ influenza virus”. Nature Biotechnology 27 (6): 510-3). Anotherexample is in the case of the amantadines treatment, which may lead tothe rapid production of resistant viruses, and over-use of these drugshas probably contributed to the spread of resistance (Lynch J P, Walsh EE (April 2007). “Influenza: evolving strategies in treatment andprevention”. Semin Respir Crit Care Med 28 (2): 144-58.).

Meanwhile, however, a few strains resistant to neuraminidase inhibitorshave emerged and circulated in the absence of much use of the drugsinvolved, and the frequency with which drug resistant strains appearsshows little correlation with the level of use of these drugs (LackenbyA, Thompson C I, Democratis J (December 2008). “The potential impact ofneuraminidase inhibitor resistant influenza”. Curr. Opin. Infect. Dis.21 (6): 626-38.). Laboratory studies have also shown that it is possiblefor the use of sub-optimal doses of these drugs as a prophylacticmeasure contributing to the development of drug resistance (Lackenby A,Thompson C I, Democratis J (December 2008). “The potential impact ofneuraminidase inhibitor resistant influenza”. Curr. Opin. Infect. Dis.21 (6): 626-38). Search for a newer class of anti-influenza virus withpotency and less side-effects has become a challenge to the bio-medicalcommunity.

SUMMARY OF THE INVENTION

One purpose of the disclosure is to provide an analgesic peptide withthe amino acid sequence as shown in SEQ ID NO: 5, its variant andderivative. Surprisingly, this peptide also shows anti-influenza A virusactivity.

Another purpose of the disclosure is to provide polynucleotides encodingthe peptide, its variant and/or derivative.

Still another purpose of the disclosure is to provide the preparationand uses of the peptide, its variant and/or derivative.

In one aspect, the present disclosure provides an isolated peptidecomprising the amino acid sequence as shown in SEQ ID NO: 5, itsconserved variants, its active fragments, and its active derivatives.Preferably, said peptide has the amino acid sequence of DEAQETAVSSHEQDas shown in SEQ ID NO: 5.

In another aspect, the present disclosure provides an isolated peptidecomprising an amino acid sequence sharing at least 50% homology, forexample, at least 60% homology, at least 70% homology, at least 80%homology or at least 90% homology, to the amino acid sequence as shownin SEQ ID NO: 5 and possessing the analgesic and/or anti-influenza Avirus activity.

In another aspect, the present disclosure provides an isolated peptidecomprising an amino acid sequence having one to seven (for example, one,two, three, four, five, six or seven) conserved amino acid substitutionscompared to the amino acid sequence as shown in SEQ ID NO: 5 andpossessing the analgesic and/or anti-influenza A virus activity.

In another aspect, the peptide disclosed herein, its variant and/orderivative are obtained by chemical synthesis.

In another aspect, the present disclosure provides an isolatedpolynucleotide comprising a nucleotide sequence sharing at least 50%homology to a nucleotide sequence selected from the group consisting of:

-   (a) a nucleotide sequence encoding a peptide comprising the amino    acid sequence as shown in SEQ ID NO: 5, its variant and/or    derivative, and-   (b) the polynucleotide complementary to nucleotide sequence of (a);

wherein said peptide, its variant and/or derivative possessing theanalgesic and/or anti-influenza A virus activity.

In another aspect, the present disclosure provides an isolatedpolynucleotide which encodes a peptide comprising the amino acidsequence as shown in SEQ ID NO: 5.

In another aspect, the present disclosure provides a vector comprisingthe above polynucleotide, and a host cell transformed with the vector orpolynucleotide.

In another aspect, the present disclosure provides a method forproducing a peptide having the activity of the peptide as shown in SEQID NO: 5, which comprises:

-   (a) culturing the above transformed host cell under the expression    conditions;-   (b) isolating the peptide of the present invention from the culture.

In another aspect, the present disclosure provides compounds thatstimulate, promote and antagonize the activity of peptide as shown inSEQ ID NO: 5.

In another aspect, the present disclosure provides a pharmaceuticalcomposition comprising an efficient amount of the peptide herein, itsvariant and/or derivative, and a pharmaceutically acceptable carrier.This pharmaceutical composition can be used to treat or relief thediseases and/or symptoms associated with pain in a subject. The diseasesand/or symptoms associated with pain herein include, but not limited tothose selected from all kinds of symptomatic neuralgia,lumbago,—cholecystagia, angina, arterial embolism pains, acute painsfrom wound, burn and scald, pains in surgery or post-surgery, pepticulcer pain, dysmenorrhea, labor pains posterior to childbirth, headache,pains induced by various tumor. This pharmaceutical composition can alsobe used to inhibit the activity of influenza A virus in a subject. Theinfluenza A virus herein preferably is selected from H5N1 and H1N1.

In another aspect, the present disclosure provides a method for thetreatment of the diseases and/or symptoms associated with pain in asubject, the method comprising the administration to the subject of aneffective amount of a peptide herein, its variant and/or derivative.

In another aspect, the present disclosure provides a method for theinhibition of the activity of influenza A virus in a subject, whereinthe method comprising the administration to the subject of an effectiveamount of a peptide herein, its variant and/or derivative.

In another aspect, the present disclosure provides the use of a peptideherein, its variant and/or derivative in the preparation of a medicamentfor the treatment or remission of the diseases and/or symptomsassociated with pain in a subject.

In another aspect, the present disclosure provides the use of a peptideherein, its variant and/or derivative in the preparation of a medicamentfor the inhibition of the activity of influenza A virus in a subject.

The other aspects of invention will be apparent to artisan in light ofthe teaching of the disclosure.

All publications mentioned in this specification are herein incorporatedby reference to the same extent as if each individual publication wasspecifically and individually indicated to be incorporated by referencein its entirety unless otherwise specifically noted.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings illustrate the embodiments, and do not limit thescope of invention defined in the claims.

FIG. 1. Schematic representation of the procedures used for screeningpeptide/small peptide-level analgesic agents from crude extracts of theinflammatory rabbit skins induced by inoculation of Vaccinia virus.

FIG. 2. Identification of functional peptide(s). The MS/MS spectrum ofthe doubly charged ion m/z 772.745 is shown. The amino acid sequence asshown in SEQ ID NO: 5 was determined from MS differences in the y- andb-fragment ions series and matched residues 1-14 of rabbitα1-antiproteinase.

FIG. 3. The peptide 5 (SEQ ID NO: 5) has the most superiorpain-relieving effect to other peptides and is comparable to 1 mgmorphine, as shown by a significant delay in the onset of the paininduced by intra-peritoneal injection of acetic acid (n=6). Note:p<0.005 between peptide 5 vs peptide 1, 2, 3, 4, or 6; p>0.05 betweenpeptide 5 vs morphine; and control: water alone.

FIG. 4. Peptide 5 as shown in SEQ ID NO: 5 also caused significantreduction in the total writhing number in 30 minutes after acetic acidinjection (n=6). Note: p<0.01 between peptide 5 vs peptide 1, 2, 3, 4,or 6; p>0.05 between peptide 5 vs morphine. Control: water alone.

FIG. 5. Peptide 5 possessed potent analgesic effects of neurogenicorigin. In thermal stimulation, treatment with intra-peritonealinjection of 2 mg peptide 5 as shown in SEQ ID NO: 5 (DEAQETAVSSHEQD)significantly reduced the temperature-induced pain of the sciatic nerveinjuried limb (hyperalgesia). Data are expressed as mean±SD in times(seconds). N=6. Note: **p<0.005 (by ANOVA) between untreated and treatedinjuried ipsilateral limb on day 5, 10 or 30.

FIG. 6. Peptide 5 as shown in SEQ ID NO: 5 possessed potent effects overthermal allodynia of limbs with or without nerve injury. In mechanicalstimulation, treatment with intra-peritoneal injection of 2 mg peptide 5as shown in SEQ ID NO: 5 significantly reduced the thermal allodynia ofthe sciatic nerve injuried limb. Data are expressed as mean□SD in vonFoley hair threshold (in grams). N=6 per time point. Note: **p<0.005 (byANOVA) between untreated and treated injury-ipsilateral limb on day 5,10 or 30.

FIG. 7. Peptide 5 as shown in SEQ ID NO: 5 has potent effects ininhibiting the replication of H5N1 and H1N1 viruses in vitro. Peptide 5as shown in SEQ ID NO: 5 was dissolved in pure water and was added (0,0.001, 0.01, 0.1, 1 and 10 μM) into the monolayered MDCK cells that weresimultaneously infected by various strains of H5N1 (left panel) or H1N1viruses (right panel) at 5,000 pfu/ml. After 3 days, the plaque numberwas counted manually and was normalized against the untreated control(i.e., 0 μM).

Note:

For A/Vietnam/1194/04(H5N1):

-   (1) No statistical significance between no treatment and treatment    with 0.1 μM-   (2) p<0.01 between no treatment and treatment with 1 μM-   (3) p<0.001 between no treatment and treatment with 10 μM

Whereas for both A/Hong Kong/97(H5N1) and A/goose/Taichung/Q156/05(H5N1):

-   (1) p<0.05 between no treatment and treatment with 0.1 μM-   (2) p<0.005 between no treatment and treatment with 1 μM-   (3) p<0.001 between no treatment and treatment with 10 μM

For pandemic H1N1/2009:

-   (1) no statistical significance between no treatment and 0.01 μM-   (2) p<0.05 between no treatment and treatment with 0.1 μM-   (3) p<0.005 between no treatment and treatment with 1 μM-   (4) p<0.001 between no treatment and treatment with 10 μM

For A/Taiwan/01/86(H1N1):

-   (1) p<0.05 between no treatment and treatment with 0.01 μM-   (2) p<0.01 between no treatment and treatment with 0.1 μM-   (3) p<0.005 between no treatment and treatment with 1 μM-   (4) p<0.001 between no treatment and treatment with 10 μM.

DETAILED DESCRIPTION OF THE INVENTION

The embodiments of the peptides, pharmaceutical compositions, uses andmethods of the present disclosure are intended to be illustrative andnot limiting. Modifications and variations can be made by the skills inthe art in light of the above teachings, specifically those that maypertain to alterations in the peptides maintaining near nativefunctionally with respect to analgesic and/or anti-influenza A viruseffect. Therefore, it should be understood that changes may be made inthe particular embodiments disclosed which are within the scope of whatis described.

As used herein, the peptide with the amino acid sequence as shown in SEQID NO: 5 is a fragment of rabbit al-antiproteinase F.

As used herein, the term “isolated” refers to a substance which has beenisolated from the original environment. For naturally occurringsubstance, the original environment is the natural environment. E.g.,the polynucleotide and peptide in a naturally occurring state in theviable cells are not isolated or purified. However, if the samepolynucleotide and peptide have been isolated from other componentsnaturally accompanying them, they are isolated or purified.

The peptide of the disclosure may be a recombinant, natural, orsynthetic peptide, preferably a recombinant peptide. The peptide of thedisclosure may be a purified natural product or a chemically syntheticproduct. Alternatively, it may be produced from prokaryotic oreukaryotic hosts, such as bacteria, yeast, higher plant, insect, andmammalian cells, using recombinant techniques. According to the hostused in the recombinant production, the peptide may be glycosylated ornon-glyco sylated.

As used herein, the terms “derivative” and “variant” mean the peptidethat essentially retains the same biological functions or activity ofnatural peptide of DEAQETAVSSHEQD.

As used herein, the term “derivative” used herein includes, but is notlimited to, (i) one in which one or more of the amino acid residuesinclude a substituent group, (ii) one in which the peptide is fused withanother compound, such as a compound to increase the half-life of thepeptide (for example, polyethylene glycol), (iii) one in which theadditional amino acids are fused to the peptide, such as a leader orsecretary sequence or a sequence used for purifying peptide orproprotein, or (iv) one in which the peptide is modified by somemodifications. Such derivatives are known to the artisans based on theteachings herein.

As used herein, the term “modifications” (which do not normally alterprimary sequence) include in vivo or in vitro chemical derivation ofpeptides, e.g., acelylation, or carboxylation. Also included aremodifications of glycosylation, e.g., those made by modifying theglycosylation patterns of a peptide during its synthesis and processingor in the further processing steps, e.g., by exposing the peptide toglycosylation enzymes (e.g., mammalian glycosylating or deglycosylatingenzymes). Also included are sequences having phosphorylated amino acidresidues, e.g., phosphotyrosine, phosphoserine, phosphothronine, as wellas sequences modified to improve the resistance to proteolyticdegradation or to optimize solubility properties.

As used herein, the term “variant” includes, but is not limited to,deletions, insertions and/or substitutions of several amino acids,preferably several conserved amino acid substitutions (typically 1-7,preferably 1-6, more preferably 1-5, even more preferably 1-4, stillmore preferably 1-3, most preferably 1-2), and addition of one or moreamino acids (typically less than 20, preferably less than 10, morepreferably less than 5) at C-terminal , N-terminal or inside thepeptide. For example, the protein functions are usually unchanged whenan amino residue is substituted by a similar or analogous one, e.g.substituted with a conserved or non-conserved amino acid residue(preferably a conserved amino acid residue). Further, the addition ofone or several amino acids at C-terminal and/or N-terminal usually doesnot change the protein function.

As used herein, the term “conserved amino acid substitutions” means apeptide formed by substituting at most 7, preferably at most 6, morepreferably 5, and most preferably at most 3 amino acids with the aminoacids having substantially the same or similar property, as comparedwith the amino acid sequence of DEAQETAVSSHEQD. Preferably, theseconserved mutants are formed by the substitution according to Table 1.

TABLE 1 Initial residue Representative substitution Asp (D) Glu Glu (E)Asp Ala (A) Val; Leu; Ile Gln (Q) Asn Thr (T) Ser Val (V) Ile; Leu; Met;Phe; Ala Ser (S) Thr His (H) Asn; Gln; Lys; Arg

The polynucleotide of invention may be in the forms of DNA and RNA. DNAincludes cDNA, genomic DNA, and synthetic DNA, etc., in single strand ordouble strand form. The polynucleotide of invention may be a degeneratesequence. As used herein, the term “degenerate sequence” means thatthere are different sequences which encode the same protein due to thedegeneracy of codons.

The term “polynucleotide encoding the peptide” includes thepolynucleotide encoding said peptide and the polynucleotide comprisingadditional and/or non-encoding sequence.

The polynucleotide encoding the peptide herein can be prepared by PCRamplification, recombinant method and synthetic method. For PCRamplification, one can obtain said sequences by designing primers basedon the nucleotide sequence disclosed herein, especially the ORF, andusing cDNA library commercially available or prepared by routinetechniques in the art as a template. Once the sequence is obtained, onecan produce lots of the sequences by recombinant methods. Usually, saidsequence is cloned into a vector which is then transformed into a hostcell. The sequence is isolated from the amplified host cells usingconventional techniques.

The invention further relates to a vector comprising the polynucleotideof the disclosure, a genetic engineered host cell transformed with thevector or the polynucleotide of the disclosure, and the method forproducing the peptide by recombinant techniques.

The recombinant peptides can be expressed or produced by theconventional recombinant DNA technology (Science, 1984; 224:1431), usingthe polynucleotide sequence of invention. Generally, it comprises thefollowing steps:

-   (1) transfecting or transforming the appropriate host cells with the    polynucleotide encoding the peptide or the vector containing the    polynucleotide;-   (2) culturing the host cells in an appropriate medium;-   (3) isolating or purifying the protein from the medium or cells.

In the invention, the polynucleotide sequences herein may be insertedinto a recombinant expression vector. The term “expression vector” meansa bacterial plasmid, bacteriophage, yeast plasmid, plant virus ormammalian cell virus, such as adenovirus, retrovirus or any othervehicles known in the art. Any plasmid or vector can be used toconstruct the recombinant expression vector as long as it can replicateand is stable in the host. One important feature of expression vector isthat the expression vector typically contains a replication origin, apromoter, a marker gene as well as the translation regulatorycomponents.

The known methods can be used to construct an expression vectorcontaining the sequence herein and appropriate transcription/translationregulatory components. These methods include in vitro recombinant DNAtechnique, DNA synthesis technique, in vivo recombinant technique, etc.The DNA sequence is efficiently linked to the proper promoter in anexpression vector to direct the synthesis of mRNA. The exemplarypromoters are lac or trp promoter of E. coli; PL promoter of A phage;eukaryotic promoter including CMV immediate early promoter, HSVthymidine kinase promoter, early and late SV40 promoter, LTRs ofretrovirus and some other known promoters which control the geneexpression in the prokaryotic cells, eukaryotic cells or virus. Theexpression vector may further comprise a ribosome-binding site forinitiating the translation, transcription terminator and the like.

As used herein, the term “host cell” includes prokaryote, e.g.,bacteria; primary eukaryote, e.g., yeast; advanced eukaryotic, e.g.,mammalian cells. The representative examples are bacterial cells, e.g.,E. coli, Streptomyces, Salmonella typhimurium; fungal cells, e.g.,yeast; plant cells; insect cells e.g., Drosophila S2 or Sf9; animalcells e.g., CHO, COS or Bowes melanoma, etc.

As used herein, the term “analgesic effect” includes “anti-hyperalgesiaeffect” and “anti-allodynia effect”. However, these three terms could beused separately because they indicate pain relief in different diseasesor model.

As used herein, the term “the subject” includes human, non-humanmammalians (for example, cow, sheep, rabbit, dog, mouse, rat, monkey,etc.) and domestic poultry.

The invention also provides a pharmaceutical composition comprising safeand effective amount of the peptide herein, its variant and/orderivative in combination with a pharmaceutically acceptable carrier.Such a carrier includes but is not limited to saline, buffer solution,glucose, water, glycerin, ethanol, or the combination thereof. Thepharmaceutical formulation should be suitable for delivery method. Thepharmaceutical composition may be in the form of injections which aremade by conventional methods, using physiological saline or otheraqueous solution containing glucose or auxiliary substances. Thepharmaceutical compositions in the form of tablet or capsule may beprepared by routine methods. The pharmaceutical compositions, e.g.,injections, solutions, tablets, and capsules, should be manufacturedunder sterile conditions. The active ingredient is administrated intherapeutically effective amount, e.g., about 1 ug-50 mg/kg body weightor more per day. Moreover, the peptide of invention can be administratedtogether with other therapeutic agents.

Previous experiment evidence shows that crude extract of theinflammatory rabbit skins induced by inoculation of Vaccinia virus canexert its pharmacological effect on analgesia. To identify the exactcomponents for pain relief, as demonstrated by its parental agent AGC®,we employed a proteomic approach to determine the differences in themass-to-charge ratios (m/z) by using nano LC-MS/MS. Throughsophisticated chemical purification and database search, the inventorsidentified a peptide sequence of DEAQETAVSSHEQD that possesses potentanalgesic, anti-hyperalgesia, anti-allodynia and anti-influenza A viruseffects.

The invention is further illustrated by the following examples. Theseexamples are only intended to illustrate the invention, but not to limitthe scope of the invention. For the experimental methods in thefollowing examples, they were performed under routine conditions, e.g.,those described by Sambrook. et al., in Molecule Clone: A LaboratoryManual, New York: Cold Spring Harbor Laboratory Press, 1989, or asinstructed by the manufacturers, unless otherwise specified.

EXAMPLES Example 1 Peptide Identification

A. Samples Preparation

The mixture of the bioactive agents extracted from skin tissues ofrabbits with inflammation elicited by inoculation of the virus Vacciniavariolae was prepared as described (Y. Imai, K. Saito, S. Maeda et al.Inhibition of the release of bradykinin-like substances into theperfusate of rat hind paw by neurotropin. Jpn J Pharmacol 1984,36:104-106) and was provided by the Vanworld Pharmaceutical Co Ltd,Rugao, China, with a trade name of AGC® (10 U/mL, 25 mL/vial). Around200 μL of the crude preparation of AGC® was dried in a vacuumcentrifuge. The lyophilized material was reconstituted with 100 μL of0.5 M ammonia bicarbonate buffer (pH 8.5) containing 8 M urea and 0.5 Mdithiothreitol (DTT) for 1 hr at 37° C., and for another 2 hr at 4° C.under dark condition when 10 μL of 0.5 M iodoacetamide (IAM) was addedfor alkylation. Subsequently, the resulting solutions were then digestedwith 0.2 μg of trypsin for 18 h at 37° C., and then the trypsin-digestedsolutions were acidified by 10% trifluoroacetic acid (TFA)/H₂O to pH 3.0value. After the reaction, the totally acidified solutions were appliedonto the reverse phase C18 column pre-equilibrated with 200 μL, of 0.1%TFA/H₂O (pH 3.0). The column was also washed with 200 μL of 0.1% TFA/H₂O(pH 3.0) and then eluted with a stepwise acetonitrile gradient from 50%to 100% in 0.1% TFA at room temperature.

B. Nano-LC-MS/MS Analysis

The eluted fractions were collected, dried in a vacuum centrifuge, andthen reconstituted in 10 μL of 0.1% formic acid (FA) in H₂O and analyzedby LTQ Orbitrap XL (Thermo Fisher Scientific, San Jose, Calif.). Reversephase nano-LC separation was performed on an Agilent 1200 seriesnanoflow system (Agilent Technologies, Santa Clara, Calif.). A total of10 μL sample from fraction was loaded onto an Agilent Zorbax XDB C18precolumn (0.35 mm, 5 μm), followed by separation using a C18 column(i.d. 75 μm X 25-cm, 3 μm, Micro Tech, Fontana, Calif.). The mobilephases used were (A) 0.1% FA and (B) 0.1% FA in 100% ACN. A lineargradient from 5% to 35% (B) over a 90-min period at a flow rate of 300nL/min was applied. The peptides were analyzed in the positive ion modeby applying a voltage of 1.8 Kv to the injection needle. The MS wasoperated in a data-dependent mode, in which one full scan with m/z300-2000 in the Orbitrap (R=60 000 at m/z 400) using a rate of 30ms/scan. The six most intense peaks for fragmentation with a normalizedcollision energy value of 35% in the LTQ were selected. A repeatduration of 30 s was applied to exclude the same m/z ions from thereselection for fragmentation. The reconstituted liquid as control, alsotreated by reduction, alkylation and desalting, was acidified andsubject to nano-LC-MS/MS analysis as mentioned above, except for trypsindigestion.

C. Database Search and Identification

Peptides were identified by peak lists converted from the nanoLC-MS/MSspectra by searching against animal taxonomy in the NCBI databases forexact matches using the MASCOT search program(<http://www.matrixscience.com>; Hirosawa et al., 1993). The masstolerance of both precursor ion and fragment ions was set to 0.8 Da.Searches were performed to allow for the fixed modification ascarbamidomethylation (C), and no trypsin as an enzyme. The resultantidentification had a statistically significant (P≦0.05) peptide score(based on combined MS and MS/MS spectra) and best ion score (based onMS/MS spectra).

D. Results

The mass spectral patterns of protein fragments generated with orwithout trypsin digestion were then used for comparison with those ofpreviously known proteins deposited in databanks to confirm peptidesequences, which can be used for identification of intact proteins(protein ID). Therefore, we can achieve an extensive coverage ofpeptides by shotgun analysis, elucidate the expression profiles ofpeptides or small peptides and identify sequences as well as thebiochemical characterization. A flow chart of the methods used in thiswork and all the peptides identified with their biochemicalcharacterization are listed in Table 2. The representative peptide peakfrom MS/MS analysis was detected (FIG. 2), resulting in confidentprotein identification by MASCOT searching. The MS/MS spectrum of thedoubly charged ion m/z 772.745 is shown. The amino acid sequenceDEAQETAVSSHEQD as shown in SEQ ID NO: 5, determined from MS differencesin the y-and b-fragment ions series and matched with residues 1-14 ofrabbit α1-antiproteinase F, which is different from that in human, mouseor in cattle. In addition, it also shares no homology with the otheranalgesia-related peptides including opioid agonist DAGO. According tocomputational prediction, it is linear and is unlikely to havestructures like β-helix, β-sheet, β-turn, or bend region.

TABLE 2 Characterization of six small peptides identified by MS/MSspectra from nano LC-MS/MS analysis. Peptide sequence PI/Mass (Da)Peptide 1: DEAQETAVSSH 4.13/1173.16 Peptide 2: DEAQETAVSSHE 4.00/1302.27Peptide 3: DEAQETAVSSHEQ 4.00/1430.40 Peptide 4: EAQETAVSSHEQD4.00/1430.40 Peptide 5: DEAQETAVSSHEQD 3.83/1545.49 Peptide 6:AQETAVSSHEQD 4.13/1301.29 SEQ ID NO: 1: DEAQETAVSSH (Pepetide 1)4.13/1173.16 SEQ ID NO: 2: DEAQETAVSSHE (Pepetide 2) 4.00/1302.27 SEQ IDNO: 3: DEAQETAVSSHEQ (Pepetide 3) 4.00/1430.40 SEQ ID NO: 4:EAQETAVSSHEQD (Pepetide 4) 4.00/1430.40 SEQ ID NO: 5: DEAQETAVSSHEQD(Pepetide 5) 3.83/1545.49 SEQ ID NO: 6: AQETAVSSHEQD (Pepetide 6)4.13/1304.29

Example 2 Analgesic Effects In Vivo

The peptides were synthesized at a commercial facility of MissionBiotech Co. (MB, Taipei, Taiwan) using the solid phase Fmoc chemistryand purified by reverse phase high-performance liquid chromatography toa purity of >90% and validated by MS. The final peptide products weredissolved in DMSO for experimental use.

For acute visceral pain model in mice, C57BL/6 male mice weighing 20-25gm were intra-peritonealy injected with 1 mg morphine (as a positivecontrol) or synthetic peptide 1-6 (SEQ ID NO:1-6, 2 mg each). Thirtyminutes afterwards, mice were subsequently injected with 1 ml of 1%acetic acid intra-peritoneally. The onset of the 1^(st) writhing and thefrequency of writhing in the following 30 minutes were recorded.

The peptide 5 as shown in SEQ ID NO: 5 (a 14-amino acid peptide) hassimilar pain-relieving effects comparable to 1 mg morphine as shown indelayed latency of the paw withdrawal (FIG. 3) and reduced totalwrithing episodes measured in 30 min (FIG. 4).

Example 3 Anti-Hyperalgesia Effects

C57BL/6 male mice weighing 20-25 gm were used. Surgical procedures wereperformed under Halothane (2-3%) anesthesia. Partial sciatic nerveinjury was made by tying a tight ligature with 9-0 silk suture around ⅓to ½ the diameter of the sciatic nerve, as had been described (MalmbergA B and Basbaum A I. Pain 1998; 76:215-222). In mice with shamoperation, the sciatic nerve was exposed but not ligated. The mice weresubsequently habituated to the test environment for at least 1 hourbefore thermal test and von Foley hair test. In thermal test, the pawwithdrawal latency was determined as an indicator for pain. In the vonFoley test, the stimulus intensity was adjusted to give a 10-secondwithdrawal latency in the normal mouse, whiel the cutoff in the absenceof a response was 20 seconds. The mechanical sensitivity with von Foleyhairs was assessed by the up-down paradigm (Chaplan et al, J NeurosciMethods 1994; 53:53-66). The filament for the testing paradigm waschosen to be 0.3-gm.

The peptide 5 as shown in SEQ ID NO: 5 was tested for itsanti-hyperalgesia effects in mice receiving sciatic nerve ligation.Results from the thermal test of the sham operated mice and the nerveinjuried mice were compared in parallel on day 5, 10 and 30 after thesurgery. Results clearly demonstrated that the limbs with nerve injuryhad hyper-algesia, as demonstrated by significantly reduced pawwithdrawal latencies, compared to that of the contralateral limb orsham-operated limbs (FIG. 5). Furthermore, intra-peritoneal injection of2 mg peptide 5 as shown in SEQ ID NO: 5 (labeled as “treated”) indeedcould significantly increase the tolerance to the heat-induced pain, asdemonstrated by an increase of the paw withdrawal latency (FIG. 5), incomparison to control mice given DMSO solvent (labeled as “untreated”).

Example 4 Anti-Allodynia Effects

The same animal model in example 3 was used. The peptide 5 as shown in

SEQ ID NO: 5 was tested for its anti-allodynia effects in mice receivingsciatic nerve ligation. Results from the mechanical stimulation (vonFoley test) of the sham operated mice and the nerve injuried mice werecompared in parallel on day 5, 10 and 30 after the surgery. Resultsclearly demonstrated that the limbs with nerve injury hadhyper-allodynia, as demonstrated by significantly lower von Foleythreshold, compared to that of the contralateral limb or sham-operatedlimbs (FIG. 6). Furthermore, intra-peritoneal injection of 2 mg peptide5 as shown in SEQ ID NO: 5 (labeled as “treated”) indeed couldsignificantly increase the tolerance to mechanical stimuli, asdemonstrated by an increase of the von Foley threshold (FIG. 6), incomparison to control mice given pure water (labeled as “untreated”).

Example 5 Anti-Virus Effects

A. Viruses and Cells

The H5N1 isolates A/Vietnam/1194/04 and A/Hong Kong/97 were obtainedfrom the Department of Microbiology, the University of Hong Kong. Thevirus was used of 3×10⁵ TCID₅₀ for experiments. A/Taiwan/01/86 (H1N1)was also used at 3×10⁵ TCID₅₀ for experiments. The H5N1 experiments wereconducted in a biosafety level (BSL) 3+ containment facility. Aliquotsof stock viruses were stored at −80° C. Madin-Darby canine kidney (MDCK)cells were obtained from the American Type Culture Collection (Manassas,Va., USA) and maintained in Dulbecco's Modified Eagle's Medium (DMEM)supplemented with 10% fetal calf serum and 1% antibiotics(penicillin/streptomycin). The 50% tissue culture infectious dose(TCID₅₀) was determined in MDCK cells after incubation at 37° C. for 3days and the values were calculated by the method of Reed and Muench(Reed L J, Muench H. A simple method for estimating fifty percentendpoints. American Journal of Hygiene. 1938; 27:493-497). To determinethe effectiveness of peptide 5 as shown in SEQ ID NO: 5 in inhibitingvirus replication, the pfu/ml was compared with (divided by) the initialpfu/ml that was seeded and expressed as percentage of the initial titer(which was 5×10³ pfu/ml).

B. Viral Titer Determination by Plaque Assay

All viruses used here were initially quantified on MDCK cells todetermine infectious titer (plaque forming units per mL, pfu/ml). Inbrief, the MDCK cells were grown into monolayers in 24-well plates isinfected with the virus at 5×10³ pfu/ml after treatment with peptide 5as shown in SEQ ID NO: 5 (0.001, 0.01, 0.1, 1 and 10 μM). After 1 hrbinding at 37° C. on confluent MDCK cells, the unbound virus was gentlywashed with PBS, and overlaid with 1:1 Noble Agar (1.8%) and 2×DME-F12(supplemented with Glutamax (Invitrogen, Carlsbad, Calif.), ITS(Invitrogen), and 3 μg/ml acetylated trypsin (Sigma, St. Louis, Mo.)).After allowing agar to solidify, the plates were incubated for ˜72 hrsat 37° C. before fixing with crystal violet and counting plaque numberat each dilution. After 3 days, the plaque number was counted manuallyand was normalized against the untreated control (i.e., 0 μM).

C. Peptide 5 as Shown in SEQ ID NO: 5 Inhibits Influenza Virus H5N1 andH1N1 Replication In Vitro

To examine the inhibitory effects of peptide 5 as shown in SEQ ID NO: 5against the replication of influenza virus H5N1 and H1N1, seriallydiluted synthetic peptide 5 as shown in SEQ ID NO: 5 was supplementedinto the culture of monolayered MDCK cells in 24-well plates which hadbeen exposed to 5000 pfu/ml of H5N1 A/Vietnam/1194/04, A/Hong Kong/97and A/goose/Taichung/Q156/05, or H1N1. After 3 days, the number of viralplaques with each drug concentration was counted and plaque number wasnormalized against the untreated control (FIG. 7). It showed thatpeptide 5 as shown in SEQ ID NO: 5 has potent effects in inhibiting thereplication of H5N1 and H1N1 viruses in vitro.

Aspects of the embodiments described herein may be embodied in otherforms or carried out in other ways without departing from the spirit oressential characteristics thereof. The present disclosure is thereforeto be considered as in all aspects illustrated and not restrictive, andall changes which come within the meaning and range of equivalency areintended to be embraced therein.

1-18. (canceled)
 19. A pharmaceutical composition comprising: atherapeutically effective amount of a peptide comprising one or moresequences selected from the group consisting of: a) an amino acidsequence of DEAQETAVSSHEQD (SEQ ID NO: 5), b) an amino acid sequencesharing at least 50% homology to the amino acid sequence ofDEAQETAVSSHEQD (SEQ ID NO: 5) wherein the amino acid sequence of b)possesses analgesic activity, anti-influenza A virus activity, or bothanalgesic activity and anti-influenza A virus activity; c) an amino acidsequence having one to seven conserved amino acid substitutions comparedto the amino acid sequence of DEAQETAVSSHEQD (SEQ ID NO: 5), or avariant or derivative thereof, wherein the amino acid sequence of c)possesses analgesic activity, anti-influenza A virus activity, or bothanalgesic activity and anti-influenza A virus activity; and apharmaceutically acceptable carrier.
 20. The pharmaceutical compositionof claim 19 wherein the peptide is the amino acid sequence ofDEAQETAVSSHEQD (SEQ ID NO: 5).
 21. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence sharing at least75% homology to the amino acid sequence of DEAQETAVSSHEQD (SEQ ID NO: 5)wherein the amino acid possesses analgesic activity, anti-influenza Avirus activity, or both analgesic activity and anti-influenza A virusactivity.
 22. The pharmaceutical composition of claim 19 wherein thepeptide is an amino acid sequence sharing at least 80% homology to theamino acid sequence of DEAQETAVSSHEQD (SEQ ID NO: 5) wherein the aminoacid possesses analgesic activity, anti-influenza A virus activity, orboth analgesic activity and anti-influenza A virus activity.
 23. Thepharmaceutical composition of claim 19 wherein the peptide is an aminoacid sequence sharing at least 85% homology to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5) wherein the amino acid possessesanalgesic activity, anti-influenza A virus activity, or both analgesicactivity and anti-influenza A virus activity.
 24. The pharmaceuticalcomposition of claim 19 wherein the peptide is an amino acid sequencesharing at least 90% homology to the amino acid sequence ofDEAQETAVSSHEQD (SEQ ID NO: 5) wherein the amino acid possesses analgesicactivity, anti-influenza A virus activity, or both analgesic activityand anti-influenza A virus activity.
 25. The pharmaceutical compositionof claim 19 wherein the peptide is an amino acid sequence having one toseven conserved amino acid substitutions compared to the amino acidsequence of DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivativethereof, wherein the amino acid sequence of possesses analgesicactivity, anti-influenza A virus activity, or both analgesic activityand anti-influenza A virus activity.
 26. The pharmaceutical compositionof claim 19 wherein the peptide is an amino acid sequence having oneconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 27. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having twoconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 28. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having threeconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 29. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having fourconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 30. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having fiveconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 31. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having sixconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 32. The pharmaceutical composition ofclaim 19 wherein the peptide is an amino acid sequence having sevenconserved amino acid substitutions compared to the amino acid sequenceof DEAQETAVSSHEQD (SEQ ID NO: 5), or a variant or derivative thereof,wherein the amino acid sequence of c) possesses analgesic activity,anti-influenza A virus activity, or both analgesic activity andanti-influenza A virus activity.
 33. The pharmaceutical composition ofclaim 19 wherein the peptide is a fragment of rabbit α1-antiproteinaseF.
 34. The pharmaceutical composition of claim 19 wherein the peptidematches with residues 1-14 of rabbit α1-antiproteinase F.
 35. Thepharmaceutical composition of claim 19 wherein the peptide is arecombinant peptide.
 36. The pharmaceutical composition of claim 34wherein the peptide comprises one or more modifications selected fromthe group consisting of glycosylation, acelylation, carboxylation, andphosphorylation.
 37. The pharmaceutical composition of claim 19 whereinthe peptide is a synthetic peptide.
 38. The pharmaceutical compositionof claim 36 wherein the peptide comprises one or more modificationsselected from the group consisting of glycosylation, acelylation,carboxylation, and phosphorylation.